/Investor DB

i&i Biotech Fund — 2022 Investments

2 investments dated 2022 · listed companies and verified rows first · show all

Enzyreenzyre.comNov 2022

Enzyre develops a handheld diagnostic device that performs multiple blood coagulation assays in parallel to identify bleeding causes at the point of care.

BiotechDeep TechDigital HealthHealthtechMedical DevicesEindhoven, NL

Wim van den Broek(CEO)inWaander(CSO)

Co-investorsNovalis BiotechOost NLTakeda Ventures

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Celeris Therapeutics

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.